GENE ONLINE|News &
Opinion
Blog

2019-07-23| Asia-Pacific

Recognizable Italian Pharmaceuticals Consolidated in BIO  Asia-Taiwan Seeking Global Opportunities

by GeneOnline
Share To

BIO Asia-Taiwan, organized by Biotechnology Innovation Organization (BIO) and Taiwan Bio Industry Organization (BioTaiwan), with over 1400 booths and 18 international pavilions. Among those pavilions the Italian pavilion, leading by the Italian Trade Agency (ITA) and FederSalus will be showcasing 10 recognizable medical and health organizations presenting Italian’s medical industry strength. The 10 companies are: Aurora Bioform, Biohealth, Erbaflor, Euronational, IBSA Group, LIMHEALTH, Montefarmaco, Pharma Line, Phytoitalia, and Salix.

According to the statistics from Taiwan’s Industrial Technology Research Institute (ITRI), the biotech industry has progressed a market growth of US$165 billion since 2017, which makes Taiwan an important market for European companies when making expandation into the Asia Market.

Italian biotech and pharmaceutical industries have shown great performances in recent years. Both established in 1945, Montefarmaco and IBSA Group are the major highlights inside the Italian pavilion. Since established, Montefarmaco has been dedicated to improving the quality of life through prevention, alleviation, and disease treatmentation, while pursuing innovative and original products. Now having sales points in 20 countries, it has launched various patented packaging products, such as seal caps for dietary supplements with U.S. and E.U. patents, are available for third-party purchase. Privately owned with innovative management system, IBSA Group has created impressive yearly sales with products in different areas, and has become the fourth largest operator in the field of fertility. On the other hand, fast growing startups like Aurora Biofarma and LIMHEALTH have potentials in food supplements and pharmaceutical industry with ambition for international exportation.

With its continuous investments in scientific researches, Euronational provides innovative yet natural and effective solutions to frequent issues in general internal medicine, food supplements, skin beauty, and medical devices. Erbaflor provides natural food and nutrition supplements interpreted from ancient medicine, traditional remedies, solar energy and hypoallergenic cleanser products. Focusing on nutrition supports, Biohealth takes a new model in medicine to maintain the proper body acid-base balance and the physical health of the genitourinary system. Pharma Line, with respect for doctors, patients, and the value of lives and innovations, expands its market value via food supplements and medical devices. Phytoitalia produces and exports globally patented raw materials based on natural medicinal plants or nutraceutical products. Also on the research side, Salix provides a full one-stop service solution for pharmaceutical and nutraceutical companies, including in-vitro studies, analysis, testing, and advisory.

To face the global rising trends of biotechnology, the representative companies will showcase their exclusive food supplements and packaging technologies during BIO Asia-Taiwan, seeking international partnerships and global cooperation opportunities. The Italian pavilion welcomes further discussion and connection at Booth #L418.

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Investment Summit Highlights: Advancements in Therapeutics & Pharmaceuticals
2024-08-02
BIO Asia-Taiwan Kicks Off with the Latest Cell and Gene Therapy Developments
2024-07-24
BIO Asia-Taiwan 2022: Looking for the Exit; Startup Considerations and Strategies
2022-07-28
LATEST
Bio Asia Pacific 2024 Close ASEAN Collaborations: Catalyzing Innovation and Global Partnerships
2024-09-12
Illumina’s IVD Biomarker Test Becomes the First FDA-approved Pan-cancer Companion Diagnostics Kit
2024-09-11
Lotus Pharma Expands in Southeast Asia with Alpha Choay Acquisition from Sanofi
2024-09-06
Indian CDMO Stocks in the Spotlight: US House to Vote on BIOSECURE Act Next Week
2024-09-06
Eli Lilly Joins Forces with AI Startup Genetic Leap in $409M Deal Centered Around RNA-Targeted Drug Discovery
2024-09-06
Illumina Wins EU Court Battle, Dodges Fine, but Grail Deal Already Void
2024-09-05
Breaking New Ground for Clinical Trials with AI/ML Applications
2024-09-05
EVENT
2024-09-13
ESMO Congress 2024
Barcelona, Spain
2024-10-09
Medical Japan 2024 Tokyo
Tokyo, Japan
2024-10-15
BIO Investor Forum 2024
San Francisco, U.S.A.
Scroll to Top